Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
19.47
USD
|
+1.30%
|
|
+7.10%
|
+1.72%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,026
|
1,487
|
2,204
|
1,176
|
1,697
|
1,762
|
-
|
-
|
Enterprise Value (EV)
1 |
2,122
|
1,595
|
1,864
|
1,061
|
1,595
|
1,740
|
1,773
|
1,769
|
P/E ratio
|
454
x
|
-6.42
x
|
-78.9
x
|
-10.4
x
|
-6.02
x
|
-21
x
|
-31.4
x
|
-84.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.38
x
|
2.67
x
|
3.19
x
|
1.73
x
|
2.25
x
|
2.13
x
|
1.96
x
|
1.84
x
|
EV / Revenue
|
2.49
x
|
2.86
x
|
2.7
x
|
1.56
x
|
2.12
x
|
2.1
x
|
1.98
x
|
1.85
x
|
EV / EBITDA
|
9.73
x
|
-
|
25.9
x
|
-50.5
x
|
-253
x
|
76.2
x
|
26
x
|
16.9
x
|
EV / FCF
|
28.3
x
|
-24.7
x
|
11.5
x
|
-7
x
|
-9.16
x
|
193
x
|
73.9
x
|
34
x
|
FCF Yield
|
3.54%
|
-4.05%
|
8.7%
|
-14.3%
|
-10.9%
|
0.52%
|
1.35%
|
2.94%
|
Price to Book
|
1.84
x
|
1.69
x
|
2.28
x
|
1.33
x
|
2.2
x
|
2.76
x
|
2.79
x
|
2.63
x
|
Nbr of stocks (in thousands)
|
74,389
|
75,210
|
79,855
|
81,034
|
88,669
|
90,478
|
-
|
-
|
Reference price
2 |
27.23
|
19.78
|
27.60
|
14.51
|
19.14
|
19.47
|
19.47
|
19.47
|
Announcement Date
|
13/08/19
|
23/02/21
|
24/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
851.1
|
557
|
690.6
|
678.4
|
753.2
|
827.9
|
896.6
|
957.1
|
EBITDA
1 |
218.2
|
-
|
71.9
|
-21
|
-6.3
|
22.82
|
68.19
|
104.7
|
EBIT
1 |
145.2
|
-77.9
|
9.1
|
-32.8
|
-25.5
|
4.084
|
28.37
|
49.59
|
Operating Margin
|
17.06%
|
-13.99%
|
1.32%
|
-4.83%
|
-3.39%
|
0.49%
|
3.16%
|
5.18%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-57.1
|
-140.6
|
-262.2
|
-104.6
|
-75.29
|
-47
|
Net income
1 |
4.6
|
-
|
-27.2
|
-112
|
-263.3
|
-91.08
|
-64.5
|
-34.59
|
Net margin
|
0.54%
|
-
|
-3.94%
|
-16.51%
|
-34.96%
|
-11%
|
-7.19%
|
-3.61%
|
EPS
2 |
0.0600
|
-3.080
|
-0.3500
|
-1.390
|
-3.180
|
-0.9260
|
-0.6200
|
-0.2300
|
Free Cash Flow
1 |
75.1
|
-64.6
|
162.2
|
-151.6
|
-174.1
|
9
|
24
|
52
|
FCF margin
|
8.82%
|
-11.6%
|
23.49%
|
-22.35%
|
-23.11%
|
1.09%
|
2.68%
|
5.43%
|
FCF Conversion (EBITDA)
|
34.42%
|
-
|
225.59%
|
-
|
-
|
39.44%
|
35.2%
|
49.65%
|
FCF Conversion (Net income)
|
1,632.61%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/08/19
|
23/02/21
|
24/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
167.3
|
160.8
|
164.9
|
179.3
|
156.4
|
177.8
|
181.2
|
183.5
|
191.9
|
196.6
|
193.3
|
204
|
211.7
|
218.7
|
209.8
|
EBITDA
1 |
12.8
|
13.4
|
10.2
|
7.3
|
-17.6
|
-10.7
|
-20.5
|
-4.2
|
1.2
|
10.1
|
-5.55
|
4.4
|
9.55
|
14.3
|
-
|
EBIT
1 |
-1.4
|
0.1
|
-2.8
|
4.5
|
-20.6
|
-13.9
|
-21.9
|
-6.8
|
-2.2
|
5.7
|
-12.19
|
0.6367
|
5.796
|
9.99
|
-1.669
|
Operating Margin
|
-0.84%
|
0.06%
|
-1.7%
|
2.51%
|
-13.17%
|
-7.82%
|
-12.09%
|
-3.71%
|
-1.15%
|
2.9%
|
-6.31%
|
0.31%
|
2.74%
|
4.57%
|
-0.8%
|
Earnings before Tax (EBT)
1 |
39.8
|
-43.5
|
-26.4
|
-17.9
|
-44.2
|
-52.1
|
-52.6
|
-116.1
|
-61.2
|
-32.3
|
-34.2
|
-22.88
|
-18.58
|
-13.22
|
-22.39
|
Net income
1 |
24.6
|
-7.6
|
-20.5
|
-14.1
|
-35.1
|
-42.3
|
-54.7
|
-116.1
|
-61.3
|
-31.2
|
-31.38
|
-20.24
|
-16.04
|
-10.75
|
-20.29
|
Net margin
|
14.7%
|
-4.73%
|
-12.43%
|
-7.86%
|
-22.44%
|
-23.79%
|
-30.19%
|
-63.27%
|
-31.94%
|
-15.87%
|
-16.24%
|
-9.92%
|
-7.58%
|
-4.91%
|
-9.67%
|
EPS
2 |
0.3000
|
-0.1000
|
-0.2600
|
-0.1800
|
-0.4300
|
-0.5200
|
-0.6700
|
-1.420
|
-0.7500
|
-0.3600
|
-0.3025
|
-0.1975
|
-0.1600
|
-0.1050
|
-0.2233
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/11/21
|
24/02/22
|
05/05/22
|
04/08/22
|
01/11/22
|
28/02/23
|
03/05/23
|
03/08/23
|
06/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
96.6
|
108
|
-
|
-
|
-
|
-
|
10.9
|
7.58
|
Net Cash position
1 |
-
|
-
|
340
|
115
|
102
|
22
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.4427
x
|
-
|
-
|
-
|
-
|
-
|
0.1601
x
|
0.0724
x
|
Free Cash Flow
1 |
75.1
|
-64.6
|
162
|
-152
|
-174
|
9
|
24
|
52
|
ROE (net income / shareholders' equity)
|
12.4%
|
-5.6%
|
0.15%
|
-12.1%
|
-2.71%
|
0.33%
|
4.06%
|
8.1%
|
ROA (Net income/ Total Assets)
|
9.27%
|
-3.57%
|
0.1%
|
-1.92%
|
-1.93%
|
-5.62%
|
-4.53%
|
-1.42%
|
Assets
1 |
49.62
|
-
|
-26,667
|
5,830
|
13,662
|
1,620
|
1,425
|
2,442
|
Book Value Per Share
2 |
14.80
|
11.70
|
12.10
|
10.90
|
8.710
|
7.040
|
6.970
|
7.400
|
Cash Flow per Share
2 |
1.100
|
-
|
0.2300
|
-1.320
|
-1.340
|
0.3200
|
0.6500
|
-
|
Capex
1 |
8.6
|
10.2
|
18
|
45.3
|
63.2
|
19
|
20
|
21.5
|
Capex / Sales
|
1.01%
|
1.83%
|
2.61%
|
6.68%
|
8.39%
|
2.29%
|
2.23%
|
2.25%
|
Announcement Date
|
13/08/19
|
23/02/21
|
24/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
19.47
USD Average target price
24.08
USD Spread / Average Target +23.69% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.72% | 1.76B | | -1.89% | 12.56B | | -9.59% | 7.68B | | -1.31% | 5.29B | | +21.82% | 5.18B | | +0.02% | 4.57B | | -50.89% | 3.29B | | +6.42% | 2.6B | | -10.02% | 2.2B | | -8.29% | 1.79B |
Diagnostic & Testing Substances
|